KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-cash Items (2016 - 2025)

Historic Non-cash Items for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $4.6 million.

  • CRISPR Therapeutics AG's Non-cash Items fell 315.53% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 315.53%. This contributed to the annual value of $4.9 million for FY2024, which is 18.91% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Non-cash Items stood at $4.6 million, which was down 315.53% from $5.0 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Non-cash Items high stood at $219.1 million for Q4 2021, and its period low was $4.0 million during Q1 2021.
  • Moreover, its 5-year median value for Non-cash Items was $4.9 million (2024), whereas its average is $51.9 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Non-cash Items surged by 480190.84% in 2021, and later tumbled by 9741.45% in 2022.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Non-cash Items stood at $219.1 million in 2021, then tumbled by 85.34% to $32.1 million in 2022, then soared by 260.03% to $115.7 million in 2023, then plummeted by 95.81% to $4.9 million in 2024, then decreased by 4.39% to $4.6 million in 2025.
  • Its Non-cash Items stands at $4.6 million for Q3 2025, versus $5.0 million for Q2 2025 and $5.0 million for Q1 2025.